News|Articles|January 26, 2026

Pharmaceutical Technology Is Now PharmTech: A Sharper Name for a Smarter Industry

Listen
0:00 / 0:00

Key Takeaways

  • PharmTech is rebranding to strengthen its commitment to scientists, innovators, and executives in the pharmaceutical industry.
  • The company is introducing a new look, refined content strategy, and optimized digital experience to enhance engagement.
SHOW MORE

We're embracing who we are, magnifying engagement for scientists and innovators, personifying expertise for science-driven insights, and taking our brand and your business to the next level. Welcome to the renewed PharmTech.

Through every era of modern pharma, PharmTech has been the voice for practical, real-world strategy. We make complex breakthroughs professionally applicable, and we help drive advanced development and manufacturing every day.

Today, we’re taking our brand to the next level so we can strengthen our commitment to scientists, innovators, and C-suite leaders who trust us for science-driven insights for faster and smarter manufacturing of safe, effective, successful therapies.

We’re embracing who we are.

For nearly 50 years, we’ve officially been Pharmaceutical Technology. But we know ourselves as PharmTech. You do, too. Everyone does. Why? It’s precise. Gets right to the point. It aligns with our approach to the industry and what you expect from us.

We’re magnifying engagement.

We earned our place as the market leader by creating uniquely expert content and engaging media platforms. Through 2025, we developed a bold, new look, refined content strategy, and optimized digital experience. The design is incredible and we can’t wait for you to experience it.

We’re personifying expertise.

Our content authority comes from alignment with top experts across the field. By staying united with key opinion leaders in pharma, we can deliver impartial and objective insights. Our renewed strategy elevates these stars, giving them the spotlight they deserve through bold, accessible content built for busy industry leaders.

We’re acting like market leaders.

Call us humble. We earned #1, and we focus on excellence. But this industry is defined by competition. So, we’re putting on the gloves as the comprehensive leader in engagement with key decision-makers in pharma and biopharma. Reach, quality, and versatility—always.

We’re so excited to enter 2026 with this renewed focus. We hope you enjoy the new PharmTech experience, and we welcome any feedback you have.

-Christopher Cole
Associate Editorial Director
PharmTech


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.